Gene: CADM2

253559
IGSF4D|NECL3|Necl-3|SynCAM 2|synCAM2
cell adhesion molecule 2
protein-coding
3p12.1
Ensembl:ENSG00000175161 MIM:609938 Vega:OTTHUMG00000158990 UniprotKB:Q8N3J6
NC_000003.12
PubMed
0   ANCO-SNPs
ND
4   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.836e-1 (AD)  6.258e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LMBRD20.961
SCAMP10.956
MARCH60.952
FAM169A0.95
KIF21A0.95
EFR3A0.949
OAT0.948
ZDHHC170.947
PREPL0.946
NRXN10.945

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.61
OR4F29-0.559
CSAG1-0.498
TFPI2-0.468
SIX1-0.417
CNN2-0.414
PGF-0.405
MTRNR2L8-0.404
MTRNR2L10-0.404
KLRB1-0.404

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 affects the expression of CADM2 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of CADM2 gene27153756
D000393Air PollutantsAir Pollutants results in decreased expression of CADM2 mRNA25056781
C006780bisphenol Abisphenol A results in decreased expression of CADM2 mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of CADM2 mRNA29097150
D0151248-Bromo Cyclic Adenosine Monophosphate8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CADM2 mRNA22079614
D016572CyclosporineCyclosporine results in increased expression of CADM2 mRNA20106945
D0198131,2-Dimethylhydrazine"[APC protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in decreased expression of CADM2 mRNA"27840820
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of CADM2 mRNA29097150
D017313FenretinideFenretinide results in decreased expression of CADM2 mRNA28973697
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of CADM2 mRNA24231268
D007854LeadLead affects the expression of CADM2 mRNA28903495
C042720mercuric bromidemercuric bromide results in increased expression of CADM2 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
D008628MercuryMercury analog results in decreased expression of CADM2 mRNA25056781
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of CADM2 mRNA28001369
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of CADM2 mRNA23179753
D009532NickelNickel results in decreased expression of CADM2 mRNA24768652|2558310
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CADM2 mRNA27935865
D010100OxygenOxygen deficiency results in increased expression of CADM2 mRNA24205000
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of CADM2 mRNA26272509
C060836pioglitazone[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CADM2 mRNA27935865
C005556propionaldehydepropionaldehyde results in decreased expression of CADM2 mRNA26079696
D011441PropylthiouracilPropylthiouracil results in decreased expression of CADM2 mRNA24780913
C017947sodium arsenitesodium arsenite results in decreased expression of CADM2 mRNA25879800
D012969Sodium FluorideSodium Fluoride results in decreased expression of CADM2 mRNA27257137
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of CADM2 mRNA20055451
D013849ThimerosalThimerosal results in increased expression of CADM2 mRNA27188386
D014212TretinoinTretinoin results in decreased expression of CADM2 mRNA21934132
C012589trichostatin Atrichostatin A results in increased expression of CADM2 mRNA27188386
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of CADM2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of CADM2 mRNA23179753|2438349
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of CADM2 gene25560391
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA"27188386
C111237vorinostatvorinostat results in increased expression of CADM2 mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
GO:0034332adherens junction organization-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0030424axon-IEA-  
GO:0045202synapse-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1500931Cell-Cell communicationTAS
R-HSA-418990Adherens junctions interactionsTAS
R-HSA-421270Cell-cell junction organizationTAS
R-HSA-446728Cell junction organizationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28937693Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N=112 117). (2017 Oct)Clarke TKMol Psychiatry
27023175Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium. (2016 Mar 29)Stringer STransl Psychiatry
29391395Genome-wide analysis of self-reported risk-taking behaviour and cross-disorder genetic correlations in the UK Biobank cohort. (2018 Feb 2)Strawbridge RJTransl Psychiatry
26683835Physical activity, smoking, and genetic predisposition to obesity in people from Pakistan: the PROMIS study. (2015 Dec 18)Ahmad SBMC Med Genet